Xencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?

Key Points

• Xencor shares fell 6.7% on Wednesday, trading at about $19.07 after touching an intraday low of $19.34, on volume well below average.
• Analyst sentiment is mixed but still leans positive overall: Xencor has a Moderate Buy consensus rating and a consensus price target of $24.25, though some firms recently cut targets or reiterated sell/hold views.
• The company’s latest earnings were weak, with EPS of -$1.71 versus expectations of -$0.75 and revenue of just $4.52 million versus the $27.86 million estimate, highlighting ongoing financial pressure.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) shares traded down 6.7% during trading on Wednesday . The company traded as low as $19.34 and last traded at $19.0720. Approximately 291,286 shares traded hands during trading, a decline of 65% from the average daily volume of 826,268 shares. The stock had previously closed at $20.45.

Analyst Ratings Changes

A number of research firms have issued reports on XNCR. JPMorgan Chase & Co. increased their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a "neutral" rating in a research report on Monday, May 11th. Zacks Research upgraded shares of Xencor from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "strong sell" rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Truist Financial reduced their price objective on Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xencor presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.

Xencor Stock Performance

The company has a market cap of $1.40 billion, a P/E ratio of -8.26 and a beta of 0.86. The firm has a 50 day moving average price of $13.49 and a 200-day moving average price of $12.84.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The company's revenue for the quarter was down 86.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.66) EPS. On average, sell-side analysts forecast that Xencor, Inc. will post -3.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC grew its position in shares of Xencor by 66.8% in the first quarter. ADAR1 Capital Management LLC now owns 93,665 shares of the biopharmaceutical company's stock valued at $1,130,000 after purchasing an additional 37,500 shares during the last quarter. Quantinno Capital Management LP boosted its stake in Xencor by 21.1% during the 1st quarter. Quantinno Capital Management LP now owns 57,077 shares of the biopharmaceutical company's stock valued at $688,000 after purchasing an additional 9,943 shares during the period. Dimensional Fund Advisors LP boosted its stake in Xencor by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company's stock valued at $15,613,000 after purchasing an additional 45,599 shares during the period. Principal Financial Group Inc. grew its holdings in Xencor by 2.0% in the 1st quarter. Principal Financial Group Inc. now owns 347,078 shares of the biopharmaceutical company's stock valued at $4,186,000 after buying an additional 6,752 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in Xencor by 3,690.2% in the 1st quarter. Fifth Third Bancorp now owns 17,018 shares of the biopharmaceutical company's stock valued at $205,000 after buying an additional 16,569 shares during the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.